Neurosteroid and Cholesterol Binding to Integral Membrane Proteins
神经类固醇和胆固醇与整合膜蛋白的结合
基本信息
- 批准号:10623887
- 负责人:
- 金额:$ 55.28万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-06-01 至 2028-05-31
- 项目状态:未结题
- 来源:
- 关键词:AffinityAgonistAmino Acid SubstitutionAminobutyric AcidsAnestheticsAntidepressive AgentsBehavioralBindingBinding SitesBiologicalBiological AssayCholesterolCryoelectron MicroscopyDependenceEventFRAP1 geneFluorescenceGoalsIntegral Membrane ProteinLaboratory StudyLigandsLipidsMass Spectrum AnalysisMeasuresMediatingMembrane ProteinsMethodsMolecular ConformationNeuroprotective AgentsProtein ChemistryProteinsReaderResearchResolutionRoleSignaling MoleculeSignaling ProteinSiteSpecificitySterolsStructureSynapsesTechniquesTherapeuticWorkantagonistcholesterol analoggamma-Aminobutyric Acidinsightmonomernervous system developmentneuronal excitabilityneurosteroidsnovelprogramsprotein expressionprotein functionprotein phosphatase inhibitor-2receptorscreeningsedativesmall moleculetool
项目摘要
Project Summary
The Evers laboratory studies the binding interactions of neurosteroids and cholesterol with integral membrane
proteins, with the aim of identifying the specific binding events underlying sterol modulation of protein function.
Our major focus is on neurosteroid (NS) modulation of -aminobutyric acid type A receptors (GABAA-
R). Neurosteroids are important modulators of neuronal excitability and nervous system development with
enormous therapeutic potential as anesthetics, anti-depressants and neuro-protectants. We have shown
that there are multiple, subunit-specific binding sites for neurosteroids on GABAA receptors, each of which
contributes to the functional effects of neurosteroids. In the proposed research, we will use photolabeling
techniques to define the precise sites at which the major classes of neurosteroids bind on the most abundant
forms of synaptic and extra-synaptic GABAA receptors and determine the functional significance of each
identified binding site by assessing the effect of targeted amino acid substitutions on NS modulation of GABAA-
R currents. To identify photo-labeled residues we will utilize state-of-the-art protein chemistry and expression
techniques in conjunction with cutting edge mass spectrometry (MS) methods, including middle-down and
intact protein MS. High-resolution cryogenic-electron microscopy structures will be obtained to identify the
atomic details of novel NS binding sites and to investigate binding interactions that appear to stabilize
conformations not captured in current structures. Fluorescence-based binding assays will then be used to
measure the site-specific affinity of various NS for the identified binding sites. These assays will be
adapted to stopped-flow fluorimetry to determine the state-dependence of binding and to a plate reader
format to screen for site-specific agonists and antagonists. The long term goal of our NS program is to
develop and use site-specific NS ligands to probe the role of specific NS binding sites and GABAA-R subtypes
in the behavioral effects of endogenous NS and the mechanisms of action of NS sedatives and anesthetics.
We have also used cholesterol-analogue photolabeling to identify specific binding sites that
mediate cholesterol inhibition of the lipid scramblase, nhTMEM16, and cholesterol modulation of
mTOR1 by the lysosomal membrane protein GPR155. Both nhTMEM16 and GPR155 have two specific
cholesterol binding sites per protein monomer and we are using targeted amino acid substitution to
understand the functional role of each site. We are also developing fluorescence-based binding assays to
measure cholesterol affinity and sterol specificity for these sites. Novel cholesterol binding sites present new
targets for small molecule allosteric modulators of membrane protein function and the tools we have
developed are widely applicable to identifying binding sites on other cholesterol-modulated proteins and
screening for site-specific ligands.
项目摘要
埃弗斯实验室研究神经甾体和胆固醇与完整膜的结合相互作用
蛋白质,目的是确定蛋白质功能的固醇调节背后的特异性结合事件。
我们的主要重点是神经甾体(NS)的α-氨基丁酸A型受体(GABAA-)的调制。
R)。神经类固醇是神经元兴奋性和神经系统发育的重要调节剂,
作为麻醉剂、抗抑郁剂和神经保护剂具有巨大的治疗潜力。我们已经表明
GABAA受体上有多个神经类固醇的亚单位特异性结合位点,每个位点都
有助于神经类固醇的功能作用。在拟议的研究中,我们将使用光标记
技术,以确定精确的网站在哪些主要类别的神经类固醇结合的最丰富的
突触和突触外GABAA受体的形式,并确定每一个的功能意义
通过评估靶向氨基酸取代对GABAA的NS调节的影响,鉴定结合位点。
R电流。为了鉴定光标记的残基,我们将利用最先进的蛋白质化学和表达
技术结合尖端质谱(MS)方法,包括中下和
将获得高分辨率低温电子显微镜结构以鉴定
新的NS结合位点的原子细节,并研究似乎稳定
在当前结构中未捕获的构象。然后,将使用基于荧光素的结合试验,
测量各种NS对所鉴定的结合位点的位点特异性亲和力。这些试验将
适用于停流荧光测定法,以确定结合的状态依赖性,并适用于酶标仪
格式筛选位点特异性激动剂和拮抗剂。我们NS计划的长期目标是
开发和使用位点特异性NS配体来探测特异性NS结合位点和GABAA-R亚型的作用
内源性NS的行为效应以及NS镇静剂和麻醉剂的作用机制。
我们还使用胆固醇类似物光标记来鉴定特异性结合位点,
介导脂质乱序酶nhTMEM 16的胆固醇抑制和
mTOR 1通过溶酶体膜蛋白GPR 155。nhTMEM 16和GPR 155都具有两个特异性
每个蛋白质单体的胆固醇结合位点,我们正在使用靶向氨基酸取代,
了解每个站点的功能作用。我们还在开发基于荧光的结合分析,
测量这些位点的胆固醇亲和力和固醇特异性。新的胆固醇结合位点
膜蛋白功能的小分子变构调节剂的靶点和我们拥有的工具
所开发的方法广泛适用于鉴定其他胆固醇调节蛋白上的结合位点,
筛选位点特异性配体。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ALEX S. EVERS其他文献
ALEX S. EVERS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ALEX S. EVERS', 18)}}的其他基金
Molecular Targets of Neurosteroid Anti-depressant Action
神经类固醇抗抑郁作用的分子靶点
- 批准号:
10198242 - 财政年份:2021
- 资助金额:
$ 55.28万 - 项目类别:
Molecular Targets of Neurosteroid Anti-depressant Action
神经类固醇抗抑郁作用的分子靶点
- 批准号:
10662406 - 财政年份:2021
- 资助金额:
$ 55.28万 - 项目类别:
Molecular Targets of Neurosteroid Anti-depressant Action
神经类固醇抗抑郁作用的分子靶点
- 批准号:
10456973 - 财政年份:2021
- 资助金额:
$ 55.28万 - 项目类别:
Characterization of the pH-sensing interface of the arenavirus envelope glycoprotein GPC
沙粒病毒包膜糖蛋白 GPC pH 传感界面的表征
- 批准号:
8985941 - 财政年份:2015
- 资助金额:
$ 55.28万 - 项目类别:
Characterization of the pH-sensing interface of the arenavirus envelope glycoprotein GPC
沙粒病毒包膜糖蛋白 GPC pH 传感界面的表征
- 批准号:
9089864 - 财政年份:2015
- 资助金额:
$ 55.28万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 55.28万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 55.28万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 55.28万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 55.28万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 55.28万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 55.28万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 55.28万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 55.28万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 55.28万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 55.28万 - 项目类别:
Grant-in-Aid for Scientific Research (C)